PRE 5.32 (+1.72%)
KYG722451062Medical Diagnostics & ResearchDiagnostics & Research

Prenetics Global (PRE) Competitor Comparison

We are evaluating the key criteria listed to compare Prenetics Global (PRE) against its competitors in the Diagnostics & Research industry.

Linearity 3 years - PRE ranking 55 / 58

These are the competitors of Prenetics Global in the industry Diagnostics & Research ranked by linearity 3 years
1. DexCom DXCM
131.06
2. Qiagen QGEN
69.97
3. Exagen XGN
55.17
4. Agilent Technologies A
48.27
5. Danaher DHR
37.52
6. Ortho Clinical Diagnostics Holdings OCDX
33.4
7. Mettler-Toledo MTD
30.48
8. Exact Sciences EXAS
22.14
9. Waters WAT
16.56
10. PerkinElmer PKI
16.14
11. NeoGenomics NEO
16.12
12. Thermo Fisher Scientific TMO
12.18
13. Sera Prognostics SERA
11.5
14. Syneos Health SYNH
10.68
15. Bioventus BVS
9.81
16. IQVIA Holdings IQV
9.77
17. Anixa Biosciences ANIX
9.27
18. Laboratory Corp of America Holdings LH
9.22
19. Icon ICLR
8.86
20. Heska HSKA
7.67
21. Twist Bioscience TWST
7.63
22. Personalis PSNL
6.67
23. Olink Holding OLK
6.67
24. Sotera Health SHC
5.74
25. IDEXX Laboratories IDXX
5.49
26. Quest Diagnostics DGX
5.41
27. MaxCyte MXCT
5.04
28. Charles River Laboratories CRL
5.03
29. National Research NRC
4.29
30. Global Cord Blood CO
4.22
31. CareDx CDNA
3.95
32. Myriad Genetics MYGN
3.85
33. Pacific Biosciences of California PACB
3.45
34. Illumina ILMN
3.43
35. Guardant Health GH
3.43
36. Psychemedics PMD
2.97
37. Fulgent Genetics FLGT
2.81
38. Precipio PRPO
2.57
39. Enzo Biochem ENZ
2.57
40. Neogen NEOG
2.52
41. Biodesix BDSX
2.46
42. MDxHealth MDXH
2.28
43. Medpace Holdings MEDP
2.27
44. Lantheus Holdings LNTH
2.19
45. Inotiv NOTV
2.12
46. Trinity Biotech TRIB
2
47. Neuronetics STIM
1.98
48. Organovo Holdings ONVO
1.79
49. DarioHealth DRIO
1.79
50. Co-Diagnostics CODX
1.7
51. Interpace Biosciences IDXG
1.68
52. bioAffinity Technologies BIAF
1.55
53. SeqLL SQL
1.48
54. Aspira Womens Health AWH
1.38
55. Prenetics Global PRE
1.34
56. RadNet RDNT
1.22
57. Meridian Bioscience VIVO
0.73
58. Natera NTRA
0.33

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.